Furthermore, as AGA activity in the AGU patients is very low, the activity measurement needs to be carefully validated for the low activity range so that effect of potential treatments such as gene therapy can be accurately assessed in clinical trials. The gene discussed is AGA; the disease is aspartylglucosaminuria.